Virus therapy takes on cervical and endometrial cancers
NCT ID NCT06552598
First seen Jan 27, 2026 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This early-stage trial tests a modified virus called KD01 that is designed to infect and kill cancer cells in women with gynecologic cancers like cervical or endometrial cancer. The study has two parts: first, to find a safe dose, and second, to see if the virus can shrink tumors, especially in younger women who wish to preserve their fertility. About 97 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KD01 (a modified virus that targets and kills cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for gynecologic cancers, especially for women who want to preserve fertility.
What could go wrong
This is an early Phase I/II trial with a small number of participants. The virus may not work as hoped, and side effects could be serious. It is too soon to know if it will be effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.